Raw Sunifiram powder (314728-85-3) video
Raw Sunifiram powder (314728-85-3)
Raw Sunifiram powder, also known as DM-235, is an exciting new development in cognition enhancing supplements. It’s structurally similar to racetam nootropics but about 1,000 times stronger than piracetam.
Raw Sunifiram powder is known to work by stimulating the activity of glutamate receptors and by increasing the production and release of the “learning neurotransmitter” acetylcholine.It is believed that Raw Sunifiram powder’s primary action is that of an ampakine, which means that after crossing the blood-brain barrier it binds to AMPA-type glutamate receptors in the brain.This stimulates the production of glutamate, a vital neurotransmitter that plays a pivotal role in neural activation.
Glutamate is an excitatory neurotransmitter that is crucial to synaptic plasticity, or the ability of nerve synapses to respond to increases or decreases in activity.Raw Sunifiram powder is also thought to act as a cholinergic, increasing the production and release of the neurotransmitter acetylcholine.
Raw Sunifiram powder (314728-85-3) Specifications
| Product Name | Raw Sunifiram powder |
| Chemical Name | DM-235,1-(4-benzoylpiperazin-1-yl)propan-1-one, Piperazine |
| Brand Name | Raw Sunifiram powder, DM-235 |
| Drug Class | Nootropics |
| CAS Number | 314728-85-3 |
| InChIKey | DGOWDUFJCINDGI-UHFFFAOYSA-N |
| Molecular Formula | C14H18N2O2 |
| Molecular Weight | 246.304 g/mol |
| Monoisotopic Mass | 246.31 |
| Melting Point | 98-100°C |
| Freezing Point | No data for available |
| Biological Half-Life | 4.5-6.5 hours |
| Color | White powder |
| Solubility | Airtight, dry and ventilated |
| Storage Temperature | Store at room temperature |
| Application | Improve Memory, Improve Learning and Decrease Pain Sensitivity, etc. |
Raw Sunifiram powder (314728-85-3) Description
Sunifiram (DM-235) is a piperazine derived ampakine-like drug, It’s structurally similar to racetam nootropics but about 1,000 times stronger than piracetam. Very little research on it is currently available, but preliminary animal studies indicate that it may be a highly effective nootropic as well as a potential treatment for a variety of neurological disorders including Alzheimer’s disease, Parkinson’s disease, and amnesia.
Sunifiram was first synthesized in 2000 by scientists at the University of Firenze in Italy. Research suggests that sunifiram powder may boost brain power, mood, and energy even when taken in very low doses.
Sunifiram powder (314728-85-3) Mechanism of Action
The mechanism of action of sunifiram is unknown, but it is known to work by stimulating the activity of glutamate receptors and by increasing the production and release of the “learning neurotransmitter” acetylcholine.
Sunifiram stimulates the glutamate receptor, NMDA. It increases the rate at which glutamate (a neurotransmitter) is delivered between brain nerve cells. This can help restore memory function in damaged or surgically altered brains.
Sunifiram powder also increase the production and release of the neurotransmitter acetylcholine. Acetylcholine is closely associated with most aspects of cognition, including memory, learning speed and ability, and fluid intelligence or capacity to solve unique problems without relying on learned behaviors.
Benefits of Sunifiram powder (314728-85-3)
- Enhances Learning and Memory
- May Improve Focus, Motivation, and Mental Clarity
- Mood and Energy Booster
- Visual and Perceptual Enhancement
- Increased sex drive
Recommended Sunifiram powder (314728-85-3) Dosage
Based on a combination of user reports and information gained from animal studies, a dosage of 5-10 mg taken a maximum of three times per day is typically considered both safe and effective. It works best when dosed sublingually.
Side effects of Sunifiram powder (314728-85-3)
As of now, there do not appear to be many side effects of sunifiram powder from a research or scientific perspective.
User-reported side effects are both minor and temporary and include an increase in body temperature, increased perspiration and salivation, headache, nasal stuffiness, increased sensitivity to visual and audio stimulation, and insomnia. But it’s important to remember that no human studies or clinical trials have been conducted.
